The long-term effects of gold nanoparticles as gene vectors in a 6 hydroxydopamine-induced parkinsonian rat model

• Gold nanoparticle-mediated gene therapy provides long-term symptomatic relief in a high-dose 6-hydroxydopamine parkinsonian rat model. • Long-term striatal exposure to gold nanoparticles does not induce a neuroinflammatory response in Sprague Dawley rats. • Gene therapy attenuates 6-hydroxydopamine-induced neuroinflammation and promote dopamine biosynthesis. • Human transgenes ( AADC + GCH1 ) can be inserted and integrated into the genome of Sprague Dawley rats with gold nanoparticle-mediated gene therapy. Nanotechnology is a growing field that has widely documented the surface binding capabilities of gold nanoparticles (AuNPs). This makes them potentially useful gene vectors for the transfer of defective enzymes in Parkinson's disease (PD), a neurodegenerative disorder resulting in neuroinflammation and neuronal cell destruction. We investigated the long-term effects of AuNPs in the striatum of a 6-hydroxydopamine (6-OHDA)-induced parkinsonian rat model. AuNP-conjugated transgene constructs (AuNP-DNA) of human aromatic acid decarboxylase ( AADC ) mixed with GTP cyclohydrolase 1 ( GCH1 ) (1:1) was stereotaxically delivered to the striatum of either saline or 6-ODHA-lesioned Sprague Dawley rats. Long-term effects of AuNP-mediated gene therapy were evaluated on behavior, pro-inflammatory cytokine IL-1β expression, morphology of striatal microglia, dopamine biosynthesis and transgene expression. The 6-OHDA-induced neurobehavioral deficits were mitigated in gene therapy groups. This finding was correlated with significantly improved dopamine biosynthesis, inhibition of long-term expression of IL-1β, and suppression of sustained microglial activation. Both human AADC and GCH1 transgenes were differentially expressed in the groups that underwent gene therapy. This suggests a successful AuNP-mediated transgene expression in the striatum, allowing for effective uptake and transcription of AADC and GCH1 for DA re-synthesis. Furthermore, an IL-1β- and microglial-mediated inflammatory response was attenuated, preventing or suppressing neuroinflammation that is implicated in PD pathology. Further studies detailing the mechanism of cellular uptake and transgene expression may be useful in determining the success of AuNPs as gene vectors in PD treatment.

Authors

Institutions

Publication Details

Journal
Brain Disorders
Published
2025-02-08
DOI
https://doi.org/10.1016/j.dscb.2025.100195
Citations
1
Primary Topic
Parkinson's Disease Mechanisms and Treatments
Type
article
Field-Weighted Citation Impact
1.39
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The long-term effects of gold nanoparticles as gene vectors in a 6 hydroxydopamine-induced parkinsonian rat model

Zama Msibi, Musa V. Mabandla, Siobhan van der Vyver
1 citations
Brain Disorders
Parkinson's Disease Mechanisms and Treatments
1.39
article

The long-term effects of gold nanoparticles as gene vectors in a 6 hydroxydopamine-induced parkinsonian rat model

Zama Msibi, Musa V. Mabandla, Siobhan van der Vyver
article en
1 citations

Abstract

• Gold nanoparticle-mediated gene therapy provides long-term symptomatic relief in a high-dose 6-hydroxydopamine parkinsonian rat model. • Long-term striatal exposure to gold nanoparticles does not induce a neuroinflammatory response in Sprague Dawley rats. • Gene therapy attenuates 6-hydroxydopamine-induced neuroinflammation and promote dopamine biosynthesis. • Human transgenes ( AADC + GCH1 ) can be inserted and integrated into the genome of Sprague Dawley rats with gold nanoparticle-mediated gene therapy. Nanotechnology is a growing field that has widely documented the surface binding capabilities of gold nanoparticles (AuNPs). This makes them potentially useful gene vectors for the transfer of defective enzymes in Parkinson's disease (PD), a neurodegenerative disorder resulting in neuroinflammation and neuronal cell destruction. We investigated the long-term effects of AuNPs in the striatum of a 6-hydroxydopamine (6-OHDA)-induced parkinsonian rat model. AuNP-conjugated transgene constructs (AuNP-DNA) of human aromatic acid decarboxylase ( AADC ) mixed with GTP cyclohydrolase 1 ( GCH1 ) (1:1) was stereotaxically delivered to the striatum of either saline or 6-ODHA-lesioned Sprague Dawley rats. Long-term effects of AuNP-mediated gene therapy were evaluated on behavior, pro-inflammatory cytokine IL-1β expression, morphology of striatal microglia, dopamine biosynthesis and transgene expression. The 6-OHDA-induced neurobehavioral deficits were mitigated in gene therapy groups. This finding was correlated with significantly improved dopamine biosynthesis, inhibition of long-term expression of IL-1β, and suppression of sustained microglial activation. Both human AADC and GCH1 transgenes were differentially expressed in the groups that underwent gene therapy. This suggests a successful AuNP-mediated transgene expression in the striatum, allowing for effective uptake and transcription of AADC and GCH1 for DA re-synthesis. Furthermore, an IL-1β- and microglial-mediated inflammatory response was attenuated, preventing or suppressing neuroinflammation that is implicated in PD pathology. Further studies detailing the mechanism of cellular uptake and transgene expression may be useful in determining the success of AuNPs as gene vectors in PD treatment.

Brain DisordersVol. 17
University of KwaZulu-Natal (ZA)
Openalex Percentile: Top 24%
Parkinson's Disease Mechanisms and Treatments
1.39
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.